Skip to Content
Merck
All Photos(1)

Documents

G005955

HPLC Analysis of HSA Fusion Protein on Zenix®-C SEC-300, Effect of Mobile Phase Composition

application for HPLC

Sign Into View Organizational & Contract Pricing


About This Item

technique(s)

HPLC: suitable

test parameters

column: Zenix-C SEC-300, 30 cm x 7.8 mm I.D., 3 μm particles (Z777092)
mobile phase: 150 mM sodium phosphate buffer, pH 7.0 or (A) 150 mM sodium phosphate buffer, pH 7.0; (B) IPA; (95:5, A:B)
flow rate: 1.0 mL/min
column temp.: 25 °C
detector: UV, 280 nm
injection: 10 μL
sample: HSA fusion peptide 5 mg/mL (MW 75 kD, pl 5.0, HSA conjugated peptide in diabetes treatment)

suitability

application for HPLC

application(s)

life science and biopharma

Legal Information

Zenix is a registered trademark of Sepax Technologies

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service